Indication: COVID
A PHASE 1 STUDY OF AGENT-797 TO TREAT MODERATE TO SEVERE ACUTE RESPIRATORY SYNDROME IN COVID 19 PATIENTS
Sub-indication: COVID-19
Study Type: Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: Agentus Therapeutics
